{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"},{"groupId":"OG004","value":"65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"68"}],"units":"Participants"}],"description":"The number of participants maintaining a durable graft 12 months after transplantation. A durable graft was defined as maintenance of normal blood counts: PLT \\>50\\*10\\^9/L without transfusion for at least 2 weeks prior to the visit; hemoglobin level \\>= 10 g/dL with no erythropoietin or transfusions for at least 1 month prior to the visit; and absolute neutrophil count (ANC) \\> 1,000 (1\\*10\\^9/L) with no G-CSF for at least 1 week prior to the visit.","groups":[{"description":"Participants with non-Hodgkin's lymphoma (NHL) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma"},{"description":"Participants with Hodgkin's disease (HD) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Hodgkin's Disease"},{"description":"Participants with multiple myeloma (MM) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG002","title":"Multiple Myeloma"},{"description":"Participants with 'other' cancers (desmoplastic small round cell tumor, acute myeloid leukemia, and testicular cancer) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG003","title":"Other Cancers"},{"id":"OG004","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Participants who received autologous stem cell transplantation and were evaluable 12 months post transplant. The 3 participants who did not have durable grafts included 2 participants whose PLT level never recovered to \\>50\\*10\\^9/L and 1 who had low hemoglobin at the 12-month visit.","reportingStatus":"POSTED","timeFrame":"Approximately 13 months (12 months post transplant )","title":"Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation","type":"SECONDARY","unitOfMeasure":"Participants"}